MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinomaCheng‐Han Lin(National Yang Ming Chiao Tung University), Pei‐Jung Lu(National Cheng Kung University Hospital)OncotargetMay 18, 201610.18632/oncotarget.9444Cited by 34SaveCiteExport RISWatch citationsRelated PapersmiR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer|Breast Cancer Research|2017|170ACE2 and a Traditional Chinese Medicine Formula NRICM101 Could Alleviate the Inflammation and Pathogenic Process of Acute Lung Injury|Preprints.org|2023|2